Adam Townsend - Jan 3, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Commercial Officer
Signature
/s/ David Watson, attorney-in-fact for Adam Townsend
Stock symbol
APLS
Transactions as of
Jan 3, 2023
Transactions value $
-$178,050
Form type
4
Date filed
1/5/2023, 07:00 PM
Previous filing
Dec 7, 2022
Next filing
Jan 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $75.5K +5K +11.65% $15.09 47.9K Jan 3, 2023 Direct F1
transaction APLS Common Stock Sale -$254K -5K -10.44% $50.70 42.9K Jan 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5K -1.63% $0.00 303K Jan 3, 2023 Common Stock 5K $15.09 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from an established 10b5-1 plan.
F2 This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.
F3 This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.